Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cardio Diagnostics Holdings Inc. - Common stock (NQ:CDIO)

0.3856 +0.0556 (+16.85%)
Streaming Delayed Price Updated: 3:15 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cardio Diagnostics Holdings Inc. - Common stock

< Previous 1 2 3 Next >
Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology’s 74th Annual Scientific Session
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations
From Cardio Diagnostics
Via Business Wire
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
EQNX::TICKER_START (NASDAQ:INBS),(NASDAQ:CDIO),(NASDAQ:BIAF),(NASDAQ:TRIB),(NASDAQ:SOBR) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Cannabis Death
Exposures Cannabis Death
Trump’s “Stargate AI” Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO
Via AB Newswire
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
From FN Media Group LLC
Via GlobeNewswire
Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Announces It’s Exhibiting at the 2024 Onsite Employee Health Clinics Forum
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics to Participate in the Centers for Medicare and Medicaid Services’ (CMS) Clinical Laboratory Fee Schedule (CLFS) Annual Meeting to Secure Medicare Payment for Its Innovative Tests
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Spotlight: Healthcare and Tech VTAK, ORGO, CDIO, LAZR, VLCN
Via AB Newswire
Cardio Diagnostics Holdings, Inc. Announces the Availability of Its Clinical Tests at Family Medicine Specialists’ Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois, That Offers Walk-In Appointments Seven Days a Week
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
New Study Shows Cardio Diagnostics’ (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually
By Jeremy Golden, Benzinga 
Via TheNewswire.com
Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
American Medical Association Grants Cardio Diagnostics (NASDAQ: CDIO) Reimbursement Codes For AI-Powered Coronary Heart Disease Tests
By Jeremy Golden, Benzinga 
Via TheNewswire.com
Topics Death
Exposures Death
Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
Beyond Diagnosis: Cardio Diagnostics' Actionable Clinical Intelligence Platform Provides Personalized Insights To Help Prevent Heart Attacks
By Jeremy Golden, Benzinga 
Via TheNewswire.com
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
From Cardio Diagnostics Holdings, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.